{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:52:30Z","timestamp":1791247950266,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100024386","name":"Mississippi Division of Medicaid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03806-x","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:49:14Z","timestamp":1791200954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Adherence Patterns and Predictors of GLP-1 Receptor Agonist Use for Obesity Management in a Medicaid Population"],"prefix":"10.1007","author":[{"given":"Shadi","family":"Bazzazzadehgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ly-Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler A.","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-1817","authenticated-orcid":false,"given":"Kaustuv","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"3806_CR1","unstructured":"CDC. Adult obesity prevalence maps. Obesity. 2025. https:\/\/www.cdc.gov\/obesity\/data-and-statistics\/adult-obesity-prevalence-maps.html. Accessed 13 May\u00a02026."},{"key":"3806_CR2","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.jacc.2021.06.020","volume":"78","author":"JJ Joseph","year":"2021","unstructured":"Joseph JJ, Ortiz R, Acharya T, Golden SH, L\u00f3pez L, Deedwania P. Cardiovascular impact of race and ethnicity in patients with diabetes and obesity. J Am Coll Cardiol. 2021;78:2471\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.020.","journal-title":"J Am Coll Cardiol"},{"key":"3806_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15585\/mmwr.mm6545a4","volume":"65","author":"GL Beckles","year":"1999","unstructured":"Beckles GL, Chou C-F. Disparities in the prevalence of diagnosed diabetes - United States, 1999-2002 and 2011-2014. MMWR Morb Mortal Wkly Rep. 1999;65:1265\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm6545a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3806_CR4","unstructured":"Galewitz P. In Mississippi, Medicaid coverage of weight loss drugs fails to catch on. KFF Health News. 2025. https:\/\/kffhealthnews.org\/health-care-costs\/mississippi-medicaid-glp-1s-weight-loss-drugs-obesity\/. Accessed 13 May\u00a02026."},{"key":"3806_CR5","doi-asserted-by":"publisher","unstructured":"Wilding J, Batterham R, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","DOI":"10.1056\/NEJMoa2032183"},{"key":"3806_CR6","unstructured":"KFF health tracking poll: Prescription drug costs, views on Trump administration actions, and GLP-1 use. KFF. 2025. https:\/\/www.kff.org\/public-opinion\/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use\/. Accessed 13 May\u00a02026."},{"key":"3806_CR7","unstructured":"FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA. FDA; 2026. https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize. Accessed 13 May\u00a02026."},{"key":"3806_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/cd23-0023","volume":"41","author":"HP Whitley","year":"2023","unstructured":"Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages. Clin Diabetes. 2023;41:467\u201373. https:\/\/doi.org\/10.2337\/cd23-0023.","journal-title":"Clin Diabetes"},{"key":"3806_CR9","unstructured":"Williams E. Medicaid coverage of and spending on GLP-1s. KFF. 2026. https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s\/. Accessed 13 May\u00a02026."},{"key":"3806_CR10","unstructured":"The evolving landscape of anti-obesity medication coverage in Medicaid. https:\/\/www.milliman.com\/en\/insight\/evolving-landscape-obesity-coverage-medicaid. Accessed 13 May\u00a02026."},{"key":"3806_CR11","doi-asserted-by":"publisher","unstructured":"West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. https:\/\/doi.org\/10.1136\/bmj-2025-085304.","DOI":"10.1136\/bmj-2025-085304"},{"key":"3806_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA. 2021;325:1\u201312. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"key":"3806_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"key":"3806_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18553\/jmcp.2024.23332","volume":"30","author":"PP Gleason","year":"2024","unstructured":"Gleason PP, Urick BY, Marshall LZ, Friedlander N, Qiu Y, Leslie RS. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm. 2024;30:860\u20137. https:\/\/doi.org\/10.18553\/jmcp.2024.23332.","journal-title":"J Manag Care Spec Pharm"},{"key":"3806_CR15","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8:e2457349. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57349.","journal-title":"JAMA Netw Open"},{"key":"3806_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18553\/jmcp.2026.32.3.281","volume":"32","author":"LZ Marshall","year":"2026","unstructured":"Marshall LZ, Gleason PP, Friedlander N, Farley J, Urick BY. Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. J Manag Care Spec Pharm. 2026;32:281\u201391. https:\/\/doi.org\/10.18553\/jmcp.2026.32.3.281.","journal-title":"J Manag Care Spec Pharm"},{"key":"3806_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.18553\/jmcp.2026.32.3.271","volume":"32","author":"KB Meyer","year":"2026","unstructured":"Meyer KB, McVeigh M, Chiara AN, et al. Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population. J Manag Care Spec Pharm. 2026;32:271\u201380. https:\/\/doi.org\/10.18553\/jmcp.2026.32.3.271.","journal-title":"J Manag Care Spec Pharm"},{"key":"3806_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"key":"3806_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.18553\/jmcp.2026.32.4.507","volume":"32","author":"JG Rizk","year":"2026","unstructured":"Rizk JG, Qato DM. Transparent reporting of group-based trajectory modeling to study medication adherence: practical considerations and common pitfalls. J Manag Care Spec Pharm. 2026;32:507\u201316. https:\/\/doi.org\/10.18553\/jmcp.2026.32.4.507.","journal-title":"J Manag Care Spec Pharm"},{"key":"3806_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44\u20137. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x.","journal-title":"Value Health"},{"key":"3806_CR21","doi-asserted-by":"publisher","first-page":"e261272","DOI":"10.1001\/jamanetworkopen.2026.1272","volume":"9","author":"L Xie","year":"2026","unstructured":"Xie L, Anazco D, Chancay AH, et al. Glucagon-like peptide-1 receptor agonist switching and treatment persistence in adults without diabetes. JAMA Netw Open. 2026;9:e261272. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.1272.","journal-title":"JAMA Netw Open"},{"key":"3806_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cpt.865","volume":"103","author":"P Dillon","year":"2018","unstructured":"Dillon P, Stewart D, Smith SM, Gallagher P, Cousins G. Group-based trajectory models: assessing adherence to antihypertensive medication in older adults in a community pharmacy setting. Clin Pharmacol Ther. 2018;103:1052\u201360. https:\/\/doi.org\/10.1002\/cpt.865.","journal-title":"Clin Pharmacol Ther"},{"key":"3806_CR23","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.18553\/jmcp.2020.26.9.1138","volume":"26","author":"M Alhazami","year":"2020","unstructured":"Alhazami M, Pontinha VM, Patterson JA, Holdford DA. Medication adherence trajectories: a systematic literature review. J Manag Care Spec Pharm. 2020;26:1138\u201352. https:\/\/doi.org\/10.18553\/jmcp.2020.26.9.1138.","journal-title":"J Manag Care Spec Pharm"},{"key":"3806_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10654-020-00615-6","volume":"35","author":"M Herle","year":"2020","unstructured":"Herle M, Micali N, Abdulkadir M, et al. Identifying typical trajectories in longitudinal data: modelling strategies and interpretations. Eur J Epidemiol. 2020;35:205\u201322. https:\/\/doi.org\/10.1007\/s10654-020-00615-6.","journal-title":"Eur J Epidemiol"},{"key":"3806_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29:374\u201393. https:\/\/doi.org\/10.1177\/0049124101029003005.","journal-title":"Sociol Methods Res"},{"key":"3806_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.alcr.2019.100323","volume":"43","author":"G van der Nest","year":"2020","unstructured":"van der Nest G, Lima Passos V, Candel MJJM, van Breukelen GJP. An overview of mixture modelling for latent evolutions in longitudinal data: Modelling approaches, fit statistics and software. Adv Life Course Res. 2020;43:100323. https:\/\/doi.org\/10.1016\/j.alcr.2019.100323.","journal-title":"Adv Life Course Res"},{"key":"3806_CR27","unstructured":"Real-world trends in GLP-1 treatment persistence and prescribing for weight management. Blue Health Intelligence; 2024. https:\/\/www.bcbs.com\/media\/pdf\/BHI_Issue_Brief_GLP1_Trends.pdf. Accessed 14 May 2026."},{"key":"3806_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008150","volume":"15","author":"ME Wilder","year":"2022","unstructured":"Wilder ME, Zheng Z, Zeger SL, et al. Relationship between social determinants of health and antihypertensive medication adherence in a Medicaid cohort. Circ Cardiovasc Qual Outcomes. 2022;15:e008150. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.121.008150.","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03806-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:04:20Z","timestamp":1791245060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":28,"alternative-id":["3806"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03806-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tyler A. Vest was an Associate Editor for the\n                      American Journal of Health-System Pharmacy\n                      (AJHP), at the time of writing. John P. Bentley received grants or contracts from the Mississippi State Department of Health, Mississippi Division of Medicaid, Board of Pharmacy Specialties, Pharmacy Quality Alliance, National Institutes of Health, and Health Resources and Services Administration (subaward through the University of Mississippi Medical Center), and consulted for the Pharmacy Quality Alliance and Indegene Inc. Kaustuv Bhattacharya received grants or contracts from the Mississippi State Department of Health, Mississippi Division of Medicaid, Board of Pharmacy Specialties, Pharmacy Quality Alliance, National Institutes of Health, and Health Resources and Services Administration (subaward through the University of Mississippi Medical Center). Amy Ly-Ha, Dennis Smith, and Terri Kirby are employees of the Mississippi Division of Medicaid. Shadi Bazzazzadehgan, Eric Pittman, Liang-Yuan Lin, and Junnan Qi reported no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by MS Division of Medicaid\u2019s Privacy Board and the University of Mississippi institutional review board with a waiver of informed consent because of the retrospective nature of the data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}